Retina Foundation of the Southwest   Report issue

Foundation Phase 2 Phase 3
Founded: Dallas TX United States (1975)

Organization Overview

First Clinical Trial
1996
NCT00004827
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Retina Foundation of the Southwest

Active Ingredients

Drugs in Phase 3 Trials (1)

acetylcysteine (mucomyst) (1 trial)

Drugs in Phase 2 Trials (1)

fish oil (Omegavan) (3 trials)

Drugs in Other Trials (1)

arachidonic acid (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Genetic Diseases, Inborn (Phase 2)

Genetic Diseases, X-Linked (Phase 2)

Retinitis (Phase 2)

Retinitis Pigmentosa (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 3